Literature DB >> 23711236

Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions.

Nisha Unni1, Marie Peddinghaus, Christopher A Tormey, Gary Stack.   

Abstract

BACKGROUND: Patients transfused at more than one health care facility face safety risks, because their transfusion record is fragmented. Blood group antibodies documented at one facility may be unknown to others. Because many antibodies are evanescent, access to prior antibody records is important for preventing incompatible transfusions and delayed hemolytic reactions. The study goal was to quantify multisite transfusion activity and its impact on antibody record accuracy. STUDY DESIGN AND METHODS: Patients (n = 100) undergoing hospital transfusion testing were surveyed to determine the locations and dates of any prior transfusions. Also, transfusion records were examined to determine whether patients (n = 200) known to be alloimmunized at one hospital had antibody testing done at another nearby hospital and, if so, how often the results were discrepant.
RESULTS: Twenty-three percent (23/100) of patients undergoing type-and-screen testing reported receiving transfusions at 24 other facilities. Locations of transfusions that occurred elsewhere were 54.2% (13/24) at eight other in-state hospitals, 12.5% in bordering states, 20.8% in more distant states, and 12.5% during military service. Twenty-one percent (42/200) of patients known to be alloimmunized at one hospital had antibody test results on record at another nearby hospital. Antibody discrepancies were noted in 64.3% (27/42) of cases. The most common discrepancy was the failure of one facility to detect an antibody.
CONCLUSION: Multisite transfusions were common. For patients seen at both of two nearby hospitals, antibody records were frequently discrepant. The findings support the need for interfacility sharing of transfusion records, particularly at the regional level. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2013        PMID: 23711236     DOI: 10.1111/trf.12251

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  15 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Fragmentation in specialist care and stage III colon cancer.

Authors:  Tanvir Hussain; Hsien-Yen Chang; Christine M Veenstra; Craig Evan Pollack
Journal:  Cancer       Date:  2015-06-04       Impact factor: 6.860

3.  Out-of-Network Emergency Department Use among Managed Medicaid Beneficiaries.

Authors:  Maria C Raven; David Guzman; Alice H Chen; John Kornak; Margot Kushel
Journal:  Health Serv Res       Date:  2016-11-11       Impact factor: 3.402

4.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 5.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

Review 6.  Would a National Antibody Register contribute to improving patient outcomes?

Authors:  Zachary Powell; Nan Jiang; Rajeshwori Shrestha; Denise E Jackson
Journal:  Blood Transfus       Date:  2021-03-12       Impact factor: 3.443

Review 7.  Management of hemolytic transfusion reactions.

Authors:  Jeanne E Hendrickson; Ross M Fasano
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

8.  To Give or Not to Give: RhD Immunoglobulin for an RHD *39 Pregnant Woman with Sickle Cell Disease.

Authors:  Justin E Juskewitch; Craig D Tauscher; Sheila K Moldenhauer; Jennifer E Schieber; Eapen K Jacob; Margaret A DiGuardo
Journal:  Transfus Med Hemother       Date:  2021-02-25       Impact factor: 3.747

9.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

10.  Impact of Treatment Coordination on Overall Survival in Rectal Cancer.

Authors:  Kevin Biju; George Q Zhang; Miloslawa Stem; Rebecca Sahyoun; Bashar Safar; Chady Atallah; Jonathan E Efron; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2021-01-23       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.